Comparing efficacy of first-line atypical antipsychotics: No evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole

International Journal of Psychiatry in Clinical Practice

Volumn 9, Issue 3, 2005, Pages 204-212

  Tandon, Rajiv ^a   Jibson, Michael D ^b  

^a Florida Department of Children and Families   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Aripiprazole; Clinical trials; Efficacy; Olanzapine; Quetiapine; Risperidone; Schizophrenia; Systematic overview; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; HUMAN; MEDLINE; META ANALYSIS; NEGATIVE SYNDROME; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM; SYSTEMATIC REVIEW;

EID: 26844433258     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500510029192     Document Type: Review

References (60)

1. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215-28.
2. Meltzer HY. Outcome in schizophrenia: Beyond symptom reduction. J Clin Psychiatry 1999;60(Suppl 3):3-8.
3. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995;10(Suppl 3):105-14.
4. Bilder RM. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry 1997;42:255-64.
5. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-28.
6. McEvoy JP, Schleifer PL, Frances A. The Expert Consensus Guideline series: Treatment of schizophrenia. J Clin Psychiatry 1999;60(Suppl 11):1-80.
7. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR. The Mount Sinai Conference on the Pharmacotherapy of schizophrenia. Schizophr Bull 2002;28:5-16.
8. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58(Suppl 10):55-62.
9. Moller HJ. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: Methodological issues and clinical consequences. World J Biol Psychiatry 2000;1:75-91.
10. Chalmers TC, Celano P, Sacks HS, et al. Bias in treatment assignment in controlled clinical trials. New Engl J Med 1983;309(22):1358-61.
11. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
12. Min SK, Rhee CS, Kim CE, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: A parallel group double-blind comparative trial. Yonsei Med J 1993;34:179-90.
13. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
14. Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993;88:395-402.
15. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
16. Huttunen MO, Piepponen T, Rantanen H, et al. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: A double-blind parallel-group trial. Acta Psychiatr Scand 1995;91:271-7.
17. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995;166:712-26.
18. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and memotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996;16:38-44.
19. Nair NP. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. J Clin Psychopharmacol 1998;18:103-10.
20. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study. The Risperidone Study Group Am J Psychiatry 1998;155:499-504.
21. Peuskens J, Bech P, Moller HJ, et al. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 1999;88:107-17.
22. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999;25:721-9.
23. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berlin) 1996;124:159-67.
24. Beasley CM, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-37.
25. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
26. Jakovljevic M, Dossenbach MR, Friedel P, et al. Olanzapine HGCH Group. Olanzapine versus fluphenazine in the acute (6-week) treatment of schizophrenia. Psychiatria Danubina 1999;11:3-11.
27. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-57.
28. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-73.
29. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, "Seroquel") and haloperidol in schizophrenia. Psychol Med 2000;30:95-105.
30. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000;15:121-31.
31. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20:491-505.
32. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71.
33. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90.
34. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. Br Med J 2000;321(7273):1371-6.
35. Wachter KW. Disturbed by meta-analysis? Science 1988;241(4872):1407-8.
36. Dickersin K. The existence of publication bias and risk factors for its occurrence. J Am Med Assoc 1990;263(10):1385-9.
37. Chalmers I. Underreporting research is scientific misconduct. J Am Med Assoc 1990;263(10):1405-8.
38. American Medical Association. AMA recommends that DHHS establish a registry for all U.S. clinical trials [online]. Available at: http://www.ama-assn.org/ama/pub/article/1616-8651.html [Accessed: July 27, 2004]
39. Srisurapanont M, Maneeton N. Comparison of the efficacy and acceptability of atypical antipsychotic drugs: A meta-analysis of randomized, placebo-controlled trials. J Med Assoc Thai 1999;82(4):341-6.
40. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
41. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
42. Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual "Atypical" antipsychotic: A meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-90.
43. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 1997;154:782-91.
44. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72.
45. Carpenter WT Jr, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985;11:440-52.
46. Tandon R, Nasrallah HA. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics [letter]. Arch Gen Psychiatry 2005;in press.
47. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
48. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74.
49. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The Quetiapine Experience With Safety and Tolerability (QUEST) study. Clin Ther 2001;23:1839-54.
50. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2004;161:1837-47.
51. Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet 1991;338(8775):1127-30.
52. LeLorier J, Gregoire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. New Engl J Med 1997;337(8):536-42.
53. Moher D, Fortin P, Jadad AR, et al. Completeness of reporting of trials published in languages other than English: Implications for conduct and reporting of systematic reviews. Lancet 1996;347(8998):363-6.
54. Egger M, Zellweger-Zahner T, Schneider M, et al. Language bias in randomised controlled trials published in English and German. Lancet 1997;350(9074):326-9.
55. Simes RJ. Publication bias: The case for an international registry of clinical trials. J Clin Oncol 1986;4:1529-41.
56. Meinert CL. Toward prospective registration of clinical trials. IRB 1988;10(2):6-7.
57. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30.
58. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-55.
59. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001;158:176-84.
60. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophr Bull 29(1):15-31.